NCT05252416 2025-11-28
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Phase 1 Terminated
Blueprint Medicines Corporation
Novartis
Novartis
Novartis
Tvardi Therapeutics, Incorporated
Novartis
Novartis
Novartis
Novartis
Novartis